Trial Profile
Review Study: A Retrospective Noninterventional Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms REVIEW
- Sponsors Bayer
- 06 Jun 2015 New trial record